Ara-binofuranosyluracil

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: Ara-binofuranosyluracil
• 英文别名: 1-[(2R,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
• 化学式: C₉H₁₂N₂O₆
• 分子量: 244.2
• InChiKey: DRTQHJPVMGBUCF-JDNPWWSISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  119
• 氢给体数：
  4
• 氢受体数：
  6

ADMET

毒理性

毒性数据：小鼠（腹腔注射）：LD50 4335毫克/千克

ToxicityData:Mouse(ip): LD50 4335 mg/kg

来源:NCI Investigational Drugs

文献信息

• Novel Dideoxynucleoside Derivatives
  申请人：Kitade Yukio

  公开号：US20080064868A1

  公开（公告）日：2008-03-13

  The present invention discloses a 5′-amino-2′-fluoro-2′,5′-dideoxynucleoside derivative represented by the following formula [1]: (wherein R 1 represents a nucleic acid base which may have a protecting group; R 2 represents a hydrogen atom or a protecting group of an amino group; R 3 represents a hydrogen atom or a protecting group of a hydroxyl group); a dideoxynucleoside-insoluble carrier bound substance prepared by binding said dideoxynucleoside derivative to an insoluble carrier, and an oligonucleotide analogue into which said dideoxynucleoside derivative is introduced. The oligonucleotide analogue being introduced with a dideoxynucleoside derivative of the present invention has excellent thermal stability and also high binding affinity when duplex is formed. Also, it is anticipated that it has high resistance to nucleases. Further, the dideoxynucleoside derivative of the present invention can be used as an amidite reagent to be used for nucleic acid synthesis, and also as a starting material for solid phase synthesis of nucleic acid by binding the amidite reagent to a solid phase.

  本发明公开了由下式[1]所表示的5'-氨基-2'-氟-2',5'-二脱氧核苷衍生物（其中R1表示可能具有保护基团的核酸碱基；R2表示氢原子或氨基的保护基团；R3表示氢原子或羟基的保护基团）；通过将该二脱氧核苷衍生物与不溶性载体结合而制备的二脱氧核苷载体结合物质；以及引入了该二脱氧核苷衍生物的寡核苷酸类似物。本发明引入了含有该二脱氧核苷衍生物的寡核苷酸类似物具有优异的热稳定性，当形成双链时也具有高结合亲和力。此外，预计它具有高核酸酶抵抗力。此外，本发明的二脱氧核苷衍生物可用作用于核酸合成的酰胺酯试剂，也可作为将酰胺酯试剂结合到固相上进行核酸固相合成的起始物料。
• ODCASE INHIBITORS FOR THE TREATMENT OF MALARIA
  申请人：Kotra Lakshmi P.

  公开号：US20090221524A1

  公开（公告）日：2009-09-03

  The present invention includes methods of treating or preventing malaria by administering an anti-malarial effective amount of 6-substituted uridine derivatives to a subject need thereof. The invention also includes new 6-substituted uridine derivatives for use as therapeutics, in particular to treat malaria.

  本发明涉及通过向需要治疗或预防疟疾的受体施用抗疟疾有效量的6-取代尿嘧啶衍生物来治疗或预防疟疾的方法。本发明还包括新的6-取代尿嘧啶衍生物，用于作为治疗剂，特别是用于治疗疟疾。
• PHOTOCLEAVABLE LABELED NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING
  申请人：Wu Weidong

  公开号：US20090081686A1

  公开（公告）日：2009-03-26

  Provided are novel nucleotides, nucleoside, and their derivatives described herein, that can be used in DNA sequencing technology and other types of DNA analysis. In one embodiment, the nucleotide or nucleoside with an unprotected 3′-OH group is derivatized at the nucleobase to include a fluorescent dye attached via a linker to a photocleavable terminating group. The photocleavable-fluorescent group is designed to terminate DNA synthesis as well as be cleaved so that DNA oligomers can be sequenced efficiently in a parallel format. The design of such rapidly cleavable fluorescent groups on nucleotides and nucleosides can enhance the speed and accuracy of sequencing of large oligomers of DNA in parallel, to allow rapid whole genome sequencing, and the identification of polymorphisms and other valuable genetic information, as well as allowing further manipulation and analysis of nucleic acid molecules in their native state following cleavage of the fluorescent group.

  本文介绍了一些新型的核苷酸、核苷和它们的衍生物，可以用于DNA测序技术和其他类型的DNA分析。在一个实施例中，带有未保护的3'-OH基团的核苷酸或核苷在核碱基处衍生化，包括通过连接剂连接的荧光染料和光解终止基团。光解荧光基团旨在终止DNA合成，同时被裂解，以便在并行格式中高效地测序DNA寡聚物。在核苷酸和核苷上设计这种快速可裂解的荧光基团可以增强大型DNA寡聚物并行测序的速度和准确性，以实现快速的全基因组测序，并识别多态性和其他有价值的遗传信息，同时在裂解荧光基团后允许进一步操作和分析核酸分子的自然状态。
• Biocatalytic synthesis of aminodeoxy purine N9-beta-D-nucleosides containing 3-amino-3-deoxy-beta-D-ribofuranose, 3-amino-2,3-dideoxy-beta-D-ribofuranose, and 2-amino-2-deoxy-beta-D-ribofuranose as sugar moieties
  申请人：Barai N. Vladimir

  公开号：US20070065922A1

  公开（公告）日：2007-03-22

  Purine N 9 -β-D-nucleosides containing 3-amino-3-deoxy-β-D-ribofaranose, 3-amino-2,3-dideoxy-β-D-ribofuranose, and 2-amino-2-deoxy-β-D-ribofuranose as sugar moieties are synthesized by biocatalytic transglycosylation of purine bases and the respective 3′-amino-3′-deoxyuridine, 3′-amino-3′-deoxythymidine and 2′-amino-2′-deoxyuridine as donors of the carbohydrate moiety, and the cells of Escherichia coli as a biocatalyst or glutaraldehyde (GA) treated cells of Escherichia coli as a biocatalyst or a mixture of thymidine (uridine) phosphorylase and purine nucleoside phosphorylase.

  含有3-氨基-3-脱氧-β-D-核糖呋喃糖，3-氨基-2,3-二脱氧-β-D-核糖呋喃糖和2-氨基-2-脱氧-β-D-核糖呋喃糖作为糖基团的嘌呤N9-β-D-核苷酸，通过生物催化转基因嘌呤碱基和相应的3'-氨基-3'-脱氧尿苷、3'-氨基-3'-脱氧胸苷和2'-氨基-2'-脱氧尿苷作为碳水化合物基团供体，以大肠杆菌细胞作为生物催化剂或经戊二醛处理的大肠杆菌细胞作为生物催化剂或胸苷（尿苷）磷酸化酶和嘌呤核苷酸磷酸化酶的混合物进行合成。
• Pyrimidine Derivatives As Anticancer Agents
  申请人：Kotra Lakshmi P.

  公开号：US20100056468A1

  公开（公告）日：2010-03-04

  The present invention includes methods of treating or preventing cancer by administering an effective amount of 6-substituted pyrimidine derivatives of the Formula I to a subject need thereof:

  本发明涉及通过向需要该治疗的受体施用公式I的6-取代嘧啶衍生物的有效量来治疗或预防癌症的方法：